

Index

- adamantane 408–409, 420, 427, 429
- administration, peroral 173–174, 193
- AFM, *see* atomic force microscopy
- Alzheimer's disease 90–91, 94, 227, 410
- AmB, *see* amphotericin B
- amino acids 76, 93, 95, 270
- 3-aminopropyltriethoxysilane (APTES) 313, 354, 357, 359, 366, 379
- amoxicillin 314–315, 318
- amphotericin B (AmB) 123, 137–138, 150–152
- angiogenesis 264, 271
- antibiotics 74, 309, 315, 318–319, 324
- antibodies 2, 60, 75, 87, 91–92, 104, 212, 273, 311, 315, 377–378, 415, 464, 472
- antibody fragments 84–85, 87, 89, 378
- anticancer agents 73, 303, 310–312, 330, 466
- anticancer drugs
 - liposomal 72
 - water-soluble 311
- anticancer therapy 8, 20, 225–226, 230
 - liposomes in 72
- antioxidants 131, 152, 302, 410–411
- antitumor effects 95, 282
- aorta 216–218, 228
- apolipoproteins 210–211, 230, 235
- aptamers 77, 84–85, 91–93, 311, 416
- APTES, *see* 3-aminopropyltriethoxysilane
- atherosclerosis 89, 101, 215–216, 220, 226, 228–229
- atomic force microscopy (AFM) 185, 228
- Au capped magnetic core/
mesoporous silica shell
nanoparticles 434
- Au-LDL nanoparticles 221–222
- BECs, *see* brain endothelial cells
- bioavailability 5, 302, 308–309, 311, 395
- biocompatibility 2, 4, 7, 11–12, 15, 299, 305, 309, 321, 324, 326–327, 331, 361, 380, 395–399, 404, 407, 409, 411, 419, 424, 427, 430–433, 436, 450–453, 457, 461–463, 465, 468–469
- biodegradability 2, 7, 11, 14, 16, 316, 324, 327, 331, 449, 451
- bioimaging 386, 467–468
- bone marrow 72, 262, 264–265, 268, 279
- bovine serum albumin (BSA) 16, 301, 409
- brain 23, 72, 90, 99, 104–105, 195, 264–266, 268, 407, 435
- brain endothelial cells (BECs) 264, 266
- breast 99–100, 158–159, 265, 272, 274, 407
- breast cancer 92, 136, 160, 226, 235, 274, 311

- metastatic 87, 136, 143–144
- breast cancer cells 20, 86, 92, 100, 415, 455
- BSA, *see* bovine serum albumin
- CA, *see* cholan acid
- CAF-derived exosomes (CDEs) 269–270
- CAFs, *see* cancer-associated fibroblast
- cancer 86, 88–89, 94, 96, 98, 104, 106–107, 157–161, 208, 214–215, 224, 226, 229, 231, 257–258, 260, 262, 264, 266, 268, 270, 272, 274–278, 280, 282–283, 310–312, 324, 418, 421, 455–456
- colorectal 277–278
- neck 158–159
- pancreatic 268, 274
- cancer-associated fibroblast (CAFs) 261–262, 268–271
- cancer-associated fibroblast-derived exosomes 269–270
- cancer-associated fibroblasts 261–262, 268, 271
- cancer biomarkers 273, 275, 277
- cancer cells 85, 89, 98, 100–101, 103, 143, 258, 261–266, 268–270, 272–273, 278, 311–312, 330, 396, 400, 403, 405, 407–409, 417–418, 420, 427, 430, 433, 452, 457, 460, 464–465, 469, 474
- human 99
- cancer diagnosis 86, 283, 451
- cancer drug resistance 271, 273
- cancer exosomes 265
 - pancreatic 267
- cancer immunotherapy 278–279, 281
- cancer progression 261–263, 265, 267–269, 283
- cancer therapy 87, 258, 297, 309, 312, 386, 436, 450–451, 461, 464, 468
 - targeted 99
- carbon dots (CD) 363, 406, 409, 412, 420, 422, 427, 432, 449, 451, 467, 469–470, 474
- carbon dots, HA-functionalized 470–471
- carbon nanotubes (CNTs) 395, 449, 462–464, 467, 474
 - HA-functionalized 462–467
- carbon nanotubes, HA-functionalized 462–463, 465
- cardiovascular disease 208, 212, 214, 226–227, 229, 231–232, 418
- cationic lipids 31, 158, 233–234
- cationic liposomes 31, 104, 129
- cationic surface modification 325
- CD, *see* carbon dots
- CDEs, *see* CAF-derived exosomes
- cell lines 100, 104, 277, 279, 404, 406, 410, 415, 422
- cell penetrating peptides (CPPs) 93–95, 97
- cells
 - artificial 49–50
 - cancer 101, 272–273, 426, 431, 435
 - cancerous 311, 329, 413
 - drug-resistant cancer 273, 459, 472
 - endothelial 74, 90, 219, 261, 263, 266, 271, 305
 - epithelial 266–267, 271, 277, 432, 466
 - glioma 96–97, 264
 - HeLa 235, 260, 400–401, 404, 409, 413, 416, 418–419, 422, 424–425, 427, 429–430, 466
 - hepatic stellate 268
 - HepG2 220, 223, 429, 459
 - human 305

- malignant 72, 102–103
- MDR 100
- myeloid 232, 264–265
- pancreatic cancer 266, 271, 274, 403
- stained 379, 381
- stromal 261–262
- cerebrospinal fluid (CSF) 142–143, 153
- CEST, *see* chemical exchange saturation transfer
- CETP, *see* cholesteryl ester transfer protein
- chemical degradation 83–84
- chemical exchange saturation transfer (CEST) 216
- chemotherapy 105, 312, 429, 433, 435, 461
 - tumor-targeted 465–466
- cholanic acid (CA) 466
- cholesteryl ester transfer protein (CETP) 214
- cholesteryl sulfate 152
- chylomicrons 208, 210–211, 223, 231
- circulation, systemic 215, 230–232, 310
- cisplatin 18, 87, 103, 145, 272
- CNTs, *see* carbon nanotubes
- colloidal dispersion 152, 185
- colon 87, 310, 313, 318, 321, 329, 404, 417
- colon cancer cells, human 418, 420
- colon cancer therapy 453, 455
- colorectal cancers 87, 158–159, 277, 282
- complexes
 - liposome-nucleic acid 31, 33
 - liposome/scaffold 5, 31
- composite collagen-liposome systems 11
- composites
 - liposomal nanoparticle 21
 - liposome 4, 8, 11, 13–16, 19, 21, 23, 25, 27, 29
 - liposome-scaffold 5, 7, 33
- computed tomography (CT) 208, 215–218, 221
- contrast agents 208–209, 215–217, 219–223, 382, 409, 471
 - delivery vehicles for 209, 215
- control gels 23
- core@shell nanoparticles 360, 379, 381, 383, 385
- CPPs, *see* cell penetrating peptides
- CSF, *see* cerebrospinal fluid
- CT, *see* computed tomography
- cyclophosphamide 106, 136, 143–144
- cytoplasm 305, 396, 418, 421, 460
- cytotoxicity 21, 24, 48, 87, 95–96, 146, 227, 235, 327, 330, 400–401, 406, 408, 415, 419, 429, 432, 463
- daunorubicin (DNR) 105, 123, 137, 141, 148–149
- daunorubicin, liposomal 123
- DDSs, *see* drug delivery systems
- delivery
 - controlled 21
 - immunoliposomal 90
 - liposome-mediated 10, 33
 - nanoliposomal 148
 - nucleic acid 129, 231–233, 235
 - siRNA 94, 232–233, 425
 - topical 6, 410
 - tumor-targeted 464
- delivery scaffolds 7, 9, 11
- delivery systems
 - controlled 300, 314–315, 328
 - controlled drug 297, 301
 - gum-supported liposome 23
 - liposomal gene 31

- liposome 54, 123
- liposome-based drug 9, 71
- oral drug 302
- responsive drug 328, 404, 429–430
- delivery vehicles 49, 53, 62, 208–209, 214–215, 226, 229–230, 399
- dextran 14–16, 381
- disulfide bond 401, 407–409, 412, 420–423, 430, 433, 458
- DNA 31–32, 101, 230, 257, 261, 283, 325, 414, 416–417
- DNA aptamers 92
- DNR, *see* daunorubicin
- DOX, *see* doxorubicin
- DOX hydrochloride 139, 143
- DOX-loaded hollow MSN 426–427
- DOX-loaded MSN 405, 407–408, 420–422
- DOX-loaded particles 408, 410, 420, 423, 428
- DOX release 320, 410, 418, 420, 432–433
- doxorubicin (DOX) 8, 17, 24, 27, 88, 92, 99–100, 103, 105–106, 122, 132, 140, 143–145, 230, 235, 310–312, 320–322, 330, 400–401, 404–405, 408–409, 418–420, 422, 426–427, 429–432, 434–435, 453, 455, 458–460, 464–466
- doxorubicin
 - liposomal 10, 92
 - liposome-encapsulated 17, 24
- drug carriers, inorganic
 - mesoporous 297, 299, 301
- drug delivery
 - controlled 300, 458
 - imaging-guided 468, 473–474
 - imaging-guided targeted 468, 470
 - liposomal 71, 95, 121–122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160
 - liposome-scaffold systems for 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34
 - pH-responsive 458–459
 - tumor-targeted 474
- drug delivery systems (DDSs) 27, 77, 161, 228, 231, 296–297, 299, 305, 328, 386, 409, 422, 450, 452–455, 457–458, 460–461, 463–465, 472
- drug delivery vehicles 51, 53, 71, 209, 398, 432, 436, 450, 453, 456, 462, 464
- drug localization 191–192, 196
- drug resistance 257–258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282–283
- drugs
 - anti-inflammatory 73, 99, 214, 217, 329
 - anticancer 20, 76, 103, 195, 303, 309–310, 330, 385, 400, 417, 453, 461, 464, 472
 - antimicrobial 314
 - antitumor 195, 408
 - cancer 173, 272
 - chemotherapeutic 271–273, 303, 309, 452
 - cytotoxic 72, 396
 - cytotoxic anticancer 72
 - encapsulated 10, 83–84, 128, 328, 396
 - hydrophilic 10, 24, 51, 64, 122–123, 125, 131
 - hydrophobic 8, 56, 122–123, 132, 229, 234, 302, 431
 - intracellular 296
 - lipophilic 7, 84, 225
 - liposomal 72

- liposome-encapsulated 8, 73
- liposome-loaded 75
- nanoparticle-based 209
- therapeutic 301, 317, 324, 328–329, 331
- water-soluble 56, 299, 302
- dye loading degrees 360, 368, 379
- EGF, *see* epidermal growth factor
- EGFR, *see* epidermal growth factor receptor
- EHDA, *see* electro hydrodynamic atomization
- elastic liposomes 47–48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76
- electro hydrodynamic atomization (EHDA) 308, 323
- electrospinning 27–28, 30
- electrospraying 306–308, 323
- electrospun nanofibers 25, 27–29, 33
- emulsifiers 175, 177, 179–180, 184, 186, 189, 192
- encapsulation efficiency 30, 33, 52–53, 124–125, 132, 143, 155, 230, 306, 308–309
- endocytosis 26, 51, 72, 145, 193, 258, 261, 269, 325, 328, 395–397, 404, 406, 418–419, 422, 426–427
- receptor-mediated 102, 261, 451, 454
- enhanced permeability and retention (EPR) 62, 84–85, 130, 188, 224, 311, 406
- epidermal growth factor (EGF) 18, 23, 89, 219
- epidermal growth factor receptor (EGFR) 18, 87, 91, 95–96
- EPR, *see* enhanced permeability and retention
- erythromycin 314–315, 319
- ethanol injection method 124, 133–134
- evaporation, reverse phase 65–67, 125, 133
- exosomal release 260
- exosome biogenesis 258–260
- exosomes 257–283
 - cancer-derived 265
 - control 266, 279, 282
 - PDAC-derived 268
 - regular 282
 - tumor 267, 280
 - tumor-derived 265–266, 268, 280
- FA, *see* folic acid
- FAP, *see* fibroblast activation protein
- fatty acids 126–127, 175, 179, 194, 260
- fibroblast activation protein (FAP) 89
- fluorescein isothiocyanate 366, 408–409, 425, 465
- fluorescence 101, 216, 218, 221, 356, 365, 367–368, 382–383
- fluorescence imaging 208, 215–217, 219–220, 222–223
- fluorescence intensity 222, 368–369
- fluorescent dyes 15, 359–360, 380, 383
- fluorophores 208–209, 216–217, 220, 351, 354–356, 368, 370, 377
- folate receptors (FR) 98–101, 219, 221–222, 311, 427
- folic acid (FA) 98–99, 101, 104, 219, 221–222, 311, 413, 418, 426–427, 430, 464
- Förster resonance energy transfer (FRET) 217, 366, 368, 408–409

- FR, *see* folate receptors
 FRET, *see* Förster resonance energy transfer
 functional groups
 chemical 301
 organic 299–300
 reactive 59
 fungal infections 123, 150–151, 153, 303

 gadolinium 216, 218–219, 221
 gadolinium chelates 208, 216–217, 220
 gamma-cyhalothrin (GCH) 192
 gastric cancer, recurrence and metastasis of 464, 466
 gastric cancer cells 230, 272
 gastric cancer stem cells 464, 466
 GCH, *see* gamma-cyhalothrin
 Gd³⁺ ions 373–375
 gelatin 13–14, 418, 434
 gene delivery 1, 22, 30–31, 33, 122, 195, 297, 309, 324, 469–470
 liposome-scaffold systems for 30–31, 33
 gene silencing 94–95, 97, 213
 genes 1–2, 105, 122, 266, 296–297, 299, 303, 312, 325, 328
 genetic material 26, 30–31, 121
 gentamicin 26, 28, 74, 314–315, 319
 glucose 14, 182–183, 416, 423
 gold nanoparticles 24, 217–218, 222–223, 232, 418, 421
 α -synuclein-coated 418
 liposome-stabilized
 carboxylfunctionalized 24
 graphene 449, 456, 460, 474
 biocompatibility of 456
 HA-functionalized 456–457, 459, 461
 graphene-based nanomaterials, HA-functionalized 461–462
 graphene nanomaterials, HA-functionalized 457–458
 graphenes, HA-functionalized 456–457, 459, 461

 HDL, *see* high-density lipoprotein
 HDL nanoparticles 214–219
 HDL nanoparticles for siRNA delivery 233
 heat shock proteins (HSPs) 263, 282
 hepatocytes 103, 210, 235, 312
 HepG2 tumors 220
 high-density lipoprotein (HDL) 127, 208, 210–211, 214–219, 224–225, 227–229, 232–233, 235
 histidine kinase
 autophosphorylation
 inhibitors (HKAls) 314–316, 320
 HKAls, *see* histidine kinase
 autophosphorylation
 inhibitors
 HMSNs, *see* hollow mesoporous silica nanoparticles
 hollow mesoporous silica nanoparticles (HMSNs) 301, 305, 428
 homogenization 68–69, 176–178
 high-pressure 176, 178, 180
 HSPs, *see* heat shock proteins
 hyaluronan 450–451
 hyaluronic acid 19–20, 26, 32, 105, 262, 409, 420, 450–451, 463
 hyaluronic acid derivatives 19–20
 hyaluronic acid liposomal gel 20
 hyaluronic acid nanoparticles 19
 hydrogels 6–9, 11–13, 15–16, 21, 24, 33, 187, 395, 430

- hyaluronic acid 19–20
- liposomal 6, 10–11
- hydrogen peroxide 410
- hydrolysis 15, 65, 130, 329, 352–353, 355–357, 361, 369–370, 378, 398
- ibuprofen 300–302, 312–313, 317, 401
- IDL, *see* intermediate density lipoprotein
- ILVs, *see* intraluminal endosomal vesicles
- imaging agents 76, 229, 350–352, 364, 376, 380, 386, 414
- immunoliposomes 86–91, 104, 157
 - anti-VCAM-1- 90
 - doxorubicin-loaded 89
 - doxorubicin-loaded anti-HER2 scFv 87
 - dual ligand 104
- inorganic nanohybrids,
 - hyaluronan-functionalized 449–450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474
- inorganic nanomaterials 449–451, 474
 - HA-functionalized 451, 474–475
- inorganic nanoparticle-based drug delivery, HA-functionalized 474
- inorganic nanoparticles 51, 325, 360–361, 449
- intermediate density lipoprotein (IDL) 211
- intraluminal endosomal vesicles (ILVs) 258–260, 263
- intraparticle energy transfer 365
- IRI, *see* irinotecan
- irinotecan (IRI) 146–148, 404, 459, 461
- nanoliposomal 147
- iron oxide nanoparticles 425, 432, 472
- iron oxides 208, 222–223, 361–362, 382, 450, 472
- kidneys 61, 72, 99–100, 102, 153, 216, 306, 327, 406, 409–410, 435
- Kupffer cells 268
 - liver resident 266, 268
- large unilamellar vesicles (LUVs) 54, 68, 124–125, 133
- LCST, *see* lower critical solution temperature
- LDL, *see* low-density lipoprotein
- LDL nanoparticles 229
- levofloxacin 314, 318, 321
- ligands 85, 91, 311–312, 366, 468
- lipid bilayer of liposome 128
- lipid bilayers 11–12, 25, 47, 50, 55, 57, 60, 64, 84, 122–128, 132, 152, 209, 435
- lipid crystallization 177, 184–186, 192–193
- lipid matrix 177, 189–193
- lipid membrane 57–58, 125, 127
- lipid nanoparticles 101, 175, 177, 179, 181, 183
 - non-functionalized 100, 104
- lipoprotein-based contrast agents 215, 217, 219, 221, 223
- lipoprotein fractions 231
- lipoprotein nanoparticles 229
- lipoproteins 193, 207–218, 220, 222, 224–236
- liposomal delivery
 - aptamer-mediated 93
 - peptide-mediated 95
- liposomal delivery reagent 31
- liposomal delivery vehicle 20
- liposomal formulations 123, 131–132, 141, 144, 151

- liposomal lipids 140
- liposomal membranes 10, 73
- liposomal nanoparticles 20–21
- liposomal vincristine 123
- liposome bilayers 59, 128, 140
- liposome encapsulation 3, 71
- liposome fabrication methods 63, 65, 67, 69
- liposome membrane materials 55, 57, 59, 61
- liposome membranes 31, 56, 59, 72, 132
- liposome nanoparticle system 21
- liposome nanoparticles 20, 55
- liposome stabilization 25, 28
- liposomes 1–29, 31–33, 47–48, 50–66, 68, 70–75, 77, 83–87, 91–92, 94–95, 98–99, 102, 104–105, 107, 121–125, 127–135, 140–148, 153, 155, 161, 173, 180–181, 187–188, 190, 192–194, 196, 208–209, 260, 296, 395
 - alginate-coated 17
 - chitosan-coated phospholipid-based 6
 - conventional 129, 161
 - doxorubicin-loaded 92, 94, 105
 - dual-targeted 104
 - fundamental properties of 127, 129
 - long circulating 139
 - lyophilized 132, 151
 - multifunctional 91, 94, 101
 - multivesicular 142, 154
 - neutral 11, 129
 - non-functionalized 98, 101
 - non-PEGylated 130
 - PEGylated 20–21, 130, 157, 161
 - pH-sensitive 14, 75, 100
 - preparation of 133
 - siRNA-loaded 95
 - stabilized 75, 129
 - stealth 25
 - targeted 84–85, 104, 107
 - temperature-sensitive 17, 161
 - thermosensitive 91, 96
 - uncoated 17
- LNCaP prostate cancer cells 234
- low-density lipoprotein (LDL) 58, 208, 210–212, 214–215, 219–225, 229–230
- lower critical solution temperature (LCST) 400, 411, 420, 424, 431, 435–436
- lung cancer 93, 105, 459
- lung cancer cells 100, 271
- lungs 99, 129, 145, 151, 158, 216, 265–268, 306, 311, 327, 409–410, 465
- LUVs, *see* large unilamellar vesicles
- lyophilization 182–184
- macrophages 75, 130, 145, 149, 209, 214, 216, 235, 262, 264–265, 268, 271–272, 404, 425
- magnetic field, alternating 434–436, 473
- magnetic nanoparticles (MNPs) 397, 449, 451, 471–474
 - HA-functionalized 471–474
- magnetic resonance imaging (MRI) 17, 208, 215–216, 218–221, 223, 361, 363, 372, 375, 381, 409, 471–473
- magnetic resonance imaging contrast agents 104, 195, 220, 471–472
- materials
 - bioactive 27, 33, 52–53, 316
 - ceramic 358
 - contrast-generating 209, 215–216
- MCF-7 breast cancer cells 269
- MCF-7 cancer cells 423

- MDR, *see* multi-drug resistance
- MDSCs, *see* myeloid-derived suppressor cell
- mesenchymal stem cells 31, 262, 472
- bone marrow-derived 28–29
- mesopores 299–301, 307–309, 312, 315, 324–325, 328–329, 363, 366–367, 375, 383–384, 421–422, 424, 426, 433
- mesoporous carriers 306–308, 313–314
- mesoporous materials 297–298, 300–301, 303–304, 306–307, 351, 358
- mesoporous matrix 302, 306, 308
- mesoporous shells 361–363, 433
- mesoporous silica 297–303, 305–306, 309–310, 312–318, 321–322, 324–328, 351–352, 358, 366, 382, 396, 401, 403, 405, 407, 409, 411, 413, 415, 417, 419, 421, 423, 425, 430, 432, 436, 449–451
- ordered 298, 304, 315, 351
- mesoporous silica coating 362
- mesoporous silica materials 302, 316, 406
- mesoporous silica nanoparticles (MSNs) 301, 303, 306, 310–311, 314–315, 318–321, 323, 325–330, 351, 357, 359, 363, 366–369, 371–375, 379, 381, 397, 402–404, 406, 408–412, 414, 416, 419–421, 423–426, 432, 435, 452–454, 456, 474
- HA-functionalized 452–454, 473
- metabolism 232
- metastases 258, 261–262, 264–265, 271, 464, 466
- microbubbles 15–16, 384
- microemulsions 174, 179–180, 355–356
- microenvironment 32, 192, 258, 261–262, 264, 268, 283
- microvesicles 273
- tumor-derived 265
- miRNAs 231–232, 235, 260, 262, 271, 277
- MLVs, *see* multilamellar vesicle
- MNPs, *see* magnetic nanoparticles
- MRI, *see* magnetic resonance imaging
- MSNs, *see* mesoporous silica nanoparticles
- multi-drug resistance (MDR) 100, 309, 312, 329–330
- multi-walled carbon nanotubes (MWCNTs) 462, 464–465, 467
- HA-functionalized 464–465, 467
- multifunctional drug delivery nanoplatfroms 467, 469
- multilamellar vesicle (MLVs) 65–66, 69–70, 84, 124–125, 135, 142
- MWCNTs, *see* multi-walled carbon nanotubes
- myeloid-derived suppressor cell (MDSCs) 92, 265
- nanocrystals 190, 195, 208–209, 217, 222
- nanoemulsions 173, 176–177, 189, 191–192, 196, 296
- nanofibers 27–30, 296
- nanohybrids 450, 453, 458, 470, 472
- nanomaterials 363, 386, 461–462, 474
- graphene-based 456, 460–462
- nanoparticle-stabilized liposomes 5
- nanoparticles 355, 361, 366, 369, 371, 374–375, 378–379
- drug-loaded 224, 405–406

- inorganic 361, 363
- natural 208–209
- polymer 173, 178, 194
- polymeric 208, 395
- polymeric drug delivery 209
- solid lipid 173–184, 186, 188–190, 192, 194, 196, 395
- nanostructured lipid carriers (NLC) 188, 190, 192–193, 195–196, 395
- nanotherapeutics 386–387, 436
- nanovehicles, HA-functionalized CNT-based 467
- near infrared light (NIR) 407, 431, 459–460
- neurodegenerative diseases 226–227, 229, 418
- NIR, *see* near infrared light
- NIR irradiation 431, 434–435, 460
- nitric oxide 227, 400, 413
- NLC, *see* nanostructured lipid carriers
- nucleic acids 30–32, 101, 208–209, 214–215, 232, 236, 258, 325–326, 459
- OI, *see* optical imaging
- one-pot synthesis 301, 308–309, 317
- optical imaging (OI) 222, 363–364, 375, 381, 468
- oral bioavailability 231
- organosilanes 353–357, 359, 361
- ovarian cancer cells 431
- pancreatic cancers 159, 271, 274
- PBMCs, *see* peripheral blood mononuclear cells
- PBS, *see* phosphate buffer saline
- PCs, *see* photon correlation spectroscopy
- PEG, *see* polyethylene glycol
- PEG-liposomes 27
- peptides 30, 52–53, 59–60, 77, 85, 93–97, 103, 107, 215, 218, 233, 279, 281, 311, 328, 407–408, 411–412, 415, 431, 459
 - amphiphilic 95
- peripheral blood mononuclear cells (PBMCs) 280
- PET, *see* positron emission tomography
- pharmacokinetics 10, 85, 151–152, 194, 196, 215, 219, 296, 474
 - liposomal drugs 132
- phase transition temperature 61, 65, 71, 126–128, 435
- phosphate buffer saline (PBS) 228, 400, 408, 424, 426, 433, 457
- phosphatidylcholine 5, 56, 126–127, 138, 158
- phosphatidylglycerol 126–127
- phospholipid bilayers 54, 84, 101, 121, 403
- phospholipid molecules 55, 126–127
- phospholipids 54–56, 65, 76, 125–128, 130–131, 133, 141–142, 147, 149, 153–155, 159, 210–211, 217, 228, 232, 234, 463
 - liposome-forming 130
- photodynamic therapy 99, 101, 154, 455, 457
- photon correlation spectroscopy (PCs) 5, 56, 149, 184–185
- photothermal therapy 385, 407, 435, 459–460
- plaques, atherosclerotic 214–217, 219, 226, 228

- poloxamer 7, 175–176, 180, 193
 polyethylene glycol (PEG) 3, 16,
 25, 58, 60, 62–63, 74, 83–84,
 101, 122–123, 129, 136,
 138–139, 157, 305, 310, 320,
 399, 409, 418, 427, 433, 452,
 457, 472
 porous materials 296–297
 inorganic 296
 porous shells 362, 382, 384–385
 positron emission tomography
 (PET) 208, 215–216, 372
 post-synthesis grafting approach
 359–360
 pre-metastatic niche formation
 266, 268
 prostate cancer 92–93, 274–275
 prostate cancer cells 233, 269,
 273
 proteins 18–19, 49, 52–53, 102,
 156, 210, 212, 216, 218, 224,
 257, 259–261, 263–264,
 272–273, 279, 282–283, 297,
 299, 326, 351, 378, 408, 410,
 418, 423–425, 456
 QDs, *see* quantum-dots
 quantum-dots (QDs) 76, 101,
 209, 217, 222–223, 361, 363,
 371, 384, 407, 434, 449–451,
 467–469, 474
 HA-functionalized 468
 surface modification of 468
 quercetin 302, 410–411

 radiolabeling 372, 384
 rapamycin 87, 90
 RBCs, *see* red blood cells
 red blood cells (RBCs) 49, 90,
 326, 401
 resveratrol 103, 312–314

 reverse microemulsion method
 354–357, 361
 RNA 231–232, 257, 261, 283
 tumor exosomal 267
 RNA interference (RNAi) 231
 RNAi, *see* RNA interference

 S-nitrosylated lipid 228
 silica 298, 300, 315, 349, 351,
 353, 355, 358, 360–361, 364,
 366, 370, 372, 375, 378–380,
 386, 396, 398–401, 419, 427,
 430–431
 hollow 426–427, 429
 magnetic 432–433, 435
 nonporous 352, 360, 362, 380,
 382, 398–399
 silica coatings 360–361
 silica materials 350–351, 398
 silica matrix 301, 307, 315, 328,
 350–352, 354, 359, 364, 366,
 372, 375, 398, 400
 silica mesopores 300, 308, 434
 silica nanoparticles 351,
 353–357, 361, 363–365, 367,
 369, 371–373, 375, 377, 379,
 384, 395–396, 398, 400, 402,
 404, 406, 408, 410, 412, 414,
 416, 418, 420, 422, 424, 426,
 430, 432, 436
 amorphous 326
 architecture 365
 bioinspired 401
 fluorescent 350, 354
 hollow mesoporous 301, 305,
 428
 magnetic 398, 434
 nonporous 351–352, 354, 359,
 377–378, 398–400
 porous 402
 silicon alkoxides 352–353
 simvastatin 214, 217, 226

- siRNA 32, 93–95, 101–103, 219, 231–235, 312, 325–326, 330, 399, 425
 - cholesterol-modified 232–233, 235
- SLN, *see* solid lipid
 - nanodispersions
- small unilamellar vesicles (SUVs) 69–70, 124–125, 132
- sol-gel process 350, 352, 354
- solid lipid nanodispersions (SLN) 173–176, 178, 180, 182, 184–196
- SPION, *see* super paramagnetic iron oxide nanoparticles
- spleen 72, 100, 129, 151, 306, 327, 409–410
- stability
 - biological 3
 - gastrointestinal 10
- stabilizers, steric 176, 186
- Stöber synthesis 355–356, 358
- sulfasalazine 312–313, 318, 323, 417
- super paramagnetic iron oxide nanoparticles (SPION) 361, 380, 473
- supercooled melt 177, 186–188, 190
- supercritical fluid 306–308
- surface functionalization 300, 319, 359–360, 380
- sustained release delivery system 312, 314
- SUVs, *see* small unilamellar vesicles
- T-cells 279
 - CD3⁺ 280
 - CD4⁺ 279
- therapeutic agents 51, 53, 71–72, 296, 450, 456
- tissues, bone 17, 27, 31
- toxic antibiotic drugs, liposomal encapsulation of 74
- transferrin 84–85, 102–105, 107, 312, 322, 408
- trehalose 182–183
- triolein 136, 138, 142, 153
- TTPs, *see* tumor targeting peptides
- tumor cells 92, 96, 105, 219, 224, 229–230, 271–272, 280–282, 403, 407, 421, 451, 453–454, 457–458
 - non-hMUC1 279
- tumor growth 87, 97, 102–104, 226, 233, 271, 433
- tumor growth inhibition 233, 235, 432
- tumor microenvironment 271, 406–407, 417, 420, 423, 428
- tumor targeting peptides (TTPs) 93, 96
- tumor tissue 72, 87, 92, 98, 129, 141, 155, 224–226, 229, 234–235, 405–407
- tumors 10, 85, 87–89, 91, 93, 99, 102, 107, 141, 146, 156–158, 214, 217, 219–222, 224, 230, 265, 275, 279, 282, 310–311, 328–330, 399, 405–407, 430, 432, 453, 458, 460, 469–470
 - solid 32, 72, 107, 141, 261, 459, 461
- UCNPs, *see* upconverting nanophosphors
- upconverting nanophosphors (UCNPs) 361, 363, 380, 382, 384
- UV irradiation 413, 429
- vaccines 21, 121, 150, 299
- vancomycin 74, 314–316, 320
- verteporfin (VPF) 154–155
- very low-density lipoprotein (VLDL) 208, 210–211, 223, 230

vesicles 57–58, 64, 67, 124, 129,
142–143, 146–147
virus-like particles (VLPs) 90
VLDL, *see* very low-density
lipoprotein

VLDL-based contrast agents 223
VLPs, *see* virus-like particles
VPF, *see* verteporfin

In the fast-developing field of nanomedicine, a broad variety of materials have been used for the development of advanced delivery systems for drugs, genes, and diagnostic agents. With the recent breakthroughs in the field, we are witnessing a new age of disease management, which is governed by precise regulation of dosage and delivery.

This book presents the advances in the use of lipid-based and inorganic nanomaterials for medical imaging, diagnosis, theranostics, and drug delivery. The materials discussed include liposome-scaffold systems, elastic liposomes, targeted liposomes, solid lipid nanoparticles, lipoproteins, exosomes, porous inorganic nanomaterials, silica nanoparticles, and inorganic nanohybrids. The book provides all available information about them and describes in detail their advantages and disadvantages and the areas where they could be utilized successfully.



Vladimir Torchilin is University Distinguished Professor of pharmaceutical sciences and the Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University, USA. His research interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy, cancer immunology, and novel imaging agents. He has published more than 450 original papers, more than 150 reviews and book chapters, and 12 books and holds more than 40 patents. Google Scholar gives more than 66,000 citations of his work with H-index of 114. Prof. Torchilin is editor-in-chief of *Drug Delivery* and *Current Drug Discovery Technologies* and is on the editorial boards of several leading journals in the field, including *Journal of Controlled Release* (review editor), *Bioconjugate Chemistry*, *Advanced Drug Delivery Reviews*, *European Journal of Pharmaceutics and Biopharmaceutics*, *Journal of Drug Targeting*, *Molecular Pharmaceutics*, and *Journal of Biomedical Nanotechnology*. He is also a Full Member of the European Academy of Sciences and Fellow of the American Institute of Medical and Biological Engineering, American Association of Pharmaceutical Scientists (AAPS), and the Controlled Release Society. He is a recipient of the 1982 Lenin Prize in Science and Technology (the highest scientific award in the former USSR), the 2005 Research Achievements in Pharmaceutics and Drug Delivery Award from the AAPS, 2007 Research Achievements Award from the Pharmaceutical Sciences World Congress, 2009 AAPS Journal Award, 2009 *International Journal of Nanomedicine* Distinguished Scientist Award, 2010 Controlled Release Society Founders Award, 2012 Life Time Achievements Award from the *Journal of Drug Targeting*, 2012 Alec Bangham Life Time Award, and 2013 Blaise Pascal Medal for Biomedicine from the European Academy of Sciences.



JENNY STANFORD
PUBLISHING

